AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11344383 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 10 ng/kg/min
Number of subjects: 130
Study 11344383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 9884269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 144
Study 9884269 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 144
Study 7915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone (0.4 mg) + Chlorpromazine (50 mg)
Number of subjects: 12
Study 7915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg) + Chlorpromazine (50 mg)
Number of subjects: 12
Study 7915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone (0.4 mg)
Number of subjects: 12
Study 7915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12
Study 7915235 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 12
Study 7915235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3173922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic villi sampling
Number of subjects: 61
Study 3173922 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 61
Study 29294635 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood maltreatment (emotional, sexual, multiple abuse experiences)
Number of subjects: 2980
Study 29294635 — intervention group
Group type: EXPERIMENTAL
Intervention: Being female
Number of subjects: 2980
Study 29294635 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing childhood sexual abuse
Number of subjects: 2980
Study 29294635 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing multiple types of abuse
Number of subjects: 2980
Study 29447342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR)
Number of subjects: 1675
Study 29447342 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Perfusion Scintigraphy (MPS)
Number of subjects: 1675
Study 28594757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine‐prilocaine cream
Number of subjects: 54
Study 28594757 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 54
Study 26290646 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025-inch GW
Number of subjects: 269
Study 26290646 — intervention group
Group type: COMPARATOR
Intervention: 0.035-inch GW
Number of subjects: 269
Study 24100322 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized phases for a small number of strong reflections prior to density modification; method involves using the centroid phase as a starting point.
Number of subjects: 0
Study 24100322 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for phase improvement in macromolecular crystallography; involves a genetic algorithm optimizing the quality of phases using skewness of the density map as a target function.
Number of subjects: 0
Study 21765365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV) based ART
Number of subjects: 38
Study 21765365 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP) based ART
Number of subjects: 38
Study 18499602 — intervention group
Group type: EXPERIMENTAL
Intervention: Passiflora incarnata (500 mg, Passipy IranDarouk)
Number of subjects: 60
Study 18499602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16595611 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1) over 10 min; followed by 0.1‐0.7 microg kg(‐1) h(‐1) i.v. infusion (Group D)
Number of subjects: 44
Study 16595611 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 20 microg kg(‐1) i.v.; followed by 0.5 mg i.v. boluses as required (Group M)
Number of subjects: 44
Study 12700794 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Iron (120 mg)
Number of subjects: 74
Study 12700794 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Iron (80 mg)
Number of subjects: 74
Study 12700794 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Zinc sulfate + Iron (120 mg)
Number of subjects: 74
Study 12700794 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (250 micro;g) + Zinc sulfate + Iron (80 mg)
Number of subjects: 74
Study 12700794 — intervention group
Group type: COMPARATOR
Intervention: Iron (120 mg) only (routine dosage)
Number of subjects: 74
Study 10993035 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patch (Climara) applied on buttocks
Number of subjects: 0
Study 10993035 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol patch (Climara) applied on abdomen
Number of subjects: 0
Study 9140141 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vanadyl sulphate (0.5 mg/kg/day)
Number of subjects: 31
Study 9140141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8101532 — intervention group
Group type: COMPARATOR
Intervention: Neurohumoral activation measured by plasma neurohormones
Number of subjects: 519
Study 3470356 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection using pistol-pressure syringe
Number of subjects: 0
Study 3470356 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal ligament injection using standard-grip syringe
Number of subjects: 0
Study 3470356 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of syringe and solution injected
Number of subjects: 0
Study 30066759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (0.015%) applied on face/scalp for 3 days
Number of subjects: 27
Study 30066759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate (0.05%) applied on forearm for 2 days
Number of subjects: 27
Study 27034455 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated interactive voice response tool providing real-time patient-reported data, with three brief interactive calls every 2 months after medication prescription.
Number of subjects: 1206
Study 27034455 — intervention group
Group type: COMPARATOR
Intervention: Non-interactive automated educational phone calls.
Number of subjects: 1206
Study 25154739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (SeR-Se-Ly + tamsulosin 0.4 mg)
Number of subjects: 225
Study 24192015 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/day)
Number of subjects: 51
Study 24192015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 21166767 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Sanyinjiao, SP6)
Number of subjects: 194
Study 21166767 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated acupoint (Xuanzhong, GB39)
Number of subjects: 194
Study 21166767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonacupoint
Number of subjects: 194
Study 21166767 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 194
Study 18853232 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal wheat bread (WB) (133 g)
Number of subjects: 4
Study 18853232 — intervention group
Group type: COMPARATOR
Intervention: Glucose (55 g) in water
Number of subjects: 4
Study 17145606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea capsules
Number of subjects: 26
Study 17145606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea tablets
Number of subjects: 26
Study 14524645 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 14524645 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent SSRI therapy
Number of subjects: 0
Study 14524645 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study 10921274 — intervention group
Group type: EXPERIMENTAL
Intervention: Forlax
Number of subjects: 0
Study 10921274 — intervention group
Group type: EXPERIMENTAL
Intervention: Forlax with prokinetics
Number of subjects: 0
Study 8922787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg daily)
Number of subjects: 164
Study 8922787 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (25-50 mg daily; 0.67 mg/kg daily for neutropenic patients)
Number of subjects: 164
Study 8922787 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 164
Study 8922787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 164
Study 1551115 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioether-lipid conjugate of ara-C (ara-CDP-DL-PTBA) at 250 mg/kg/week for 3 weeks
Number of subjects: 7
Study 1551115 — intervention group
Group type: COMPARATOR
Intervention: Saline vehicle (control)
Number of subjects: 7
Study 6364882 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimeprazine plus droperidol
Number of subjects: 60
Study 6364882 — intervention group
Group type: COMPARATOR
Intervention: Oral trimeprazine
Number of subjects: 60
Study 31221697 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1Ra treatment for 3 months
Number of subjects: 20
Study 31221697 — intervention group
Group type: COMPARATOR
Intervention: Obese subjects with diabetes
Number of subjects: 20
Study 30627180 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nebulizer suspension (Pulmicort Nebulizer)
Number of subjects: 90
Study 30627180 — intervention group
Group type: COMPARATOR
Intervention: Budesonide inhalation suspension (Pulmicort Turbuhaler)
Number of subjects: 90
Study 27632179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg daily oral administration, n = 209)
Number of subjects: 423
Study 27632179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 214)
Number of subjects: 423
Study 25379852 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery with prolonged time to surgery (TTS)
Number of subjects: 325
Study 23404424 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% tetracaine
Number of subjects: 99
Study 23404424 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine
Number of subjects: 99
Study 20441775 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (21-26 years)
Number of subjects: 42
Study 20441775 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged adults (50-55 years)
Number of subjects: 42
Study 20441775 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (70-77 years)
Number of subjects: 42
Study 18469574 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training for 6 weeks
Number of subjects: 30
Study 18469574 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group (Control)
Number of subjects: 30
Study 16435692 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous matching task at low difficulty
Number of subjects: 0
Study 16435692 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous matching task at moderate difficulty
Number of subjects: 0
Study 16435692 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous matching task at high difficulty
Number of subjects: 0
Study 16435692 — intervention group
Group type: EXPERIMENTAL
Intervention: NASA‐Task Load Index rating
Number of subjects: 0
Study 16435692 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG signals analysis using wavelet transform
Number of subjects: 0
Study 12738624 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (4 pmol. kg‐1. min‐1)
Number of subjects: 12
Study 12738624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10229249 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous sterile water injections (ISW)
Number of subjects: 34
Study 10229249 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 34
Study 10229249 — intervention group
Group type: COMPARATOR
Intervention: Standard care (back massage, whirlpool bath, and liberal mobilization)
Number of subjects: 34
Study 7890212 — intervention group
Group type: EXPERIMENTAL
Intervention: Gorging pattern (two meals daily)
Number of subjects: 8
Study 7890212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nibbling pattern (four to seven meals daily)
Number of subjects: 8
Study 1979541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine administered 30, 45, 60 or 90 min before challenge
Number of subjects: 0
Study 213092 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 21
Study 213092 — intervention group
Group type: EXPERIMENTAL
Intervention: tubocurarine
Number of subjects: 21
Study 213092 — intervention group
Group type: COMPARATOR
Intervention: no block
Number of subjects: 21
Study 30415988 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant modified FOLFIRINOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 180 mg/m2, and 5‐FU 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Number of subjects: 640
Study 30415988 — intervention group
Group type: COMPARATOR
Intervention: Modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5‐FU bolus 400 mg/m2, then 2.4 g/m2 over 46 hours) every 2 weeks for 24 weeks (12 cycles)
Number of subjects: 640
Study 30415988 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant modified FOLFIRINOX
Number of subjects: 640
Study 30415988 — intervention group
Group type: COMPARATOR
Intervention: Modified FOLFOX6
Number of subjects: 640
Study 30415988 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 640
Study 28647848 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit incision of the RWM (70 cases)
Number of subjects: 118
Study 28647848 — intervention group
Group type: COMPARATOR
Intervention: RWM cruciate incision (48 cases)
Number of subjects: 118
Study 25384542 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal treatment of myopia
Number of subjects: 240
Study 23473984 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole cannulation
Number of subjects: 140
Study 23473984 — intervention group
Group type: COMPARATOR
Intervention: Usual-practice cannulation
Number of subjects: 140
Study 21777701 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated approach utilizing physician's brief motivational interviewing and parent group sessions
Number of subjects: 0
Study 19002369 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral clodronate (Bonefos) daily over 3 years
Number of subjects: 3974
Study 16538112 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stenting alone (7 Fr stent)
Number of subjects: 52
Study 16538112 — intervention group
Group type: COMPARATOR
Intervention: Biliary stenting plus sphincterotomy (10 Fr stent)
Number of subjects: 52
Study 16538112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (biliary stenting alone and biliary stenting plus sphincterotomy)
Number of subjects: 52
Study 15513572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined growth hormone (GH) and GnRH analogue treatment
Number of subjects: 46
Study 15513572 — intervention group
Group type: COMPARATOR
Intervention: GnRH analogue treatment alone
Number of subjects: 46
Study 10654946 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (pulse oximetry targeted at 96% to 99%)
Number of subjects: 649
Study 10654946 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen (pulse oximetry targeted at 89% to 94%)
Number of subjects: 649
Study 10654946 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 649
Study 10654946 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen
Number of subjects: 649
Study 9295978 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy at the end of initial treatment (group 1)
Number of subjects: 369
Study 9295978 — intervention group
Group type: COMPARATOR
Intervention: No endoscopy at the end of initial treatment (group 2)
Number of subjects: 369
Study 9295978 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy at 6 months (group 1)
Number of subjects: 369
Study 9295978 — intervention group
Group type: COMPARATOR
Intervention: No endoscopy at 6 months (group 2)
Number of subjects: 369
Study 9295978 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy costs (group 1)
Number of subjects: 369
Study 9295978 — intervention group
Group type: COMPARATOR
Intervention: Pharmacy costs (group 2)
Number of subjects: 369
Study 8342092 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERCEED Barrier
Number of subjects: 134
Study 8342092 — intervention group
Group type: COMPARATOR
Intervention: Microsurgery alone
Number of subjects: 134
Study 3537216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day pulse chemotherapy every 3 weeks (group I)
Number of subjects: 496
Study 3537216 — intervention group
Group type: COMPARATOR
Intervention: Continuous chemotherapy (group C)
Number of subjects: 496
Study 3537216 — intervention group
Group type: COMPARATOR
Intervention: Semi-continuous chemotherapy (group G)
Number of subjects: 496
Study 3537216 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of chemotherapy
Number of subjects: 496
Study 3537216 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations in fractionation of cranial irradiation
Number of subjects: 496
Study 3537216 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial leucocyte count
Number of subjects: 496
Study 3537216 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (girls)
Number of subjects: 496
Study 30643052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 194
Study 30643052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study 27564126 — intervention group
Group type: EXPERIMENTAL
Intervention: Early class III protraction facemask treatment (PFG)
Number of subjects: 73
Study 27564126 — intervention group
Group type: COMPARATOR
Intervention: Control/no treatment (CG)
Number of subjects: 73
Study 24995559 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFAs‐enriched diet
Number of subjects: 0
Study 22920811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybercycle exergame
Number of subjects: 20
Study 22920811 — intervention group
Group type: COMPARATOR
Intervention: Standard stationary bicycle
Number of subjects: 20
Study 20181868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-deficient group
Number of subjects: 0
Study 20181868 — intervention group
Group type: COMPARATOR
Intervention: Fe-adequate group
Number of subjects: 0
Study 18937608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol bolus of 0.25 mg kg(‐1); no lockout interval; n = 50
Number of subjects: 100
Study 18937608 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist-controlled sedation (ACS) with continuous infusion of propofol 1% (3 mg kg(‐1) h(‐1); n = 50)
Number of subjects: 100
Study 16235978 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study 16235978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12427411 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 107
Study 12427411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 10707137 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin solution
Number of subjects: 30
Study 10707137 — intervention group
Group type: COMPARATOR
Intervention: Fortified tobramycin (1.5%) and cefazolin (10%) solutions (control group)
Number of subjects: 30
Study 8550186 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (MAb) 61BG 1.3, 3 micrograms per tooth, applied at 1, 3, 7, and 10 days after suppression of P. gingivalis.
Number of subjects: 14
Study 8550186 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group), applied at 1, 3, 7, and 10 days after suppression of P. gingivalis.
Number of subjects: 14
Study 8550186 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (MAb) 61BG 1.3
Number of subjects: 14
Study 1841774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose verapamil treatment (Isoptin RR, 240 mg verapamil, twice daily)
Number of subjects: 196
Study 1841774 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 196
Study 1841774 — intervention group
Group type: COMPARATOR
Intervention: Different dosages of diltiazem
Number of subjects: 196
Study 6138074 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 6138074 — intervention group
Group type: COMPARATOR
Intervention: Vesparax (barbiturate combination)
Number of subjects: 0
Study 31172446 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0276 single doses (SD) of 2–270 mg (PIC) and 45–540 mg (CD)
Number of subjects: 183
Study 31172446 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0276 multiple doses (MD) of 15–540 mg divided into two or three doses/day
Number of subjects: 183
Study 31172446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 183
Study 26879545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal paclitaxel (PTX) at 60 mg/m2 on the day of surgery and on days 14, 21, 28, 42, 49, and 56
Number of subjects: 83
Study 26879545 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel (PTX) at 80 mg/m2 on the same schedule
Number of subjects: 83
Study 25703611 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure therapy for PTSD
Number of subjects: 116
Study 22928878 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile display applied to the forearm skin transferring tactile input from an artificial hand.
Number of subjects: 10
Study 21913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 212
Study 21913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecillinam
Number of subjects: 212
Study 21913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 212
Study 21913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 212
Study 21913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 212
Study 21913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 212
Study 21913487 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanate
Number of subjects: 212
Study 19853700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control strategy
Number of subjects: 2794
Study 19853700 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2794